Advances in diagnosis mean that prostate cancer can be detected in the early stages, when options such as surgery and radiotherapy offer curative approaches and active surveillance is appropriate.
However, advanced or metastatic disease continues to challenge medical management, which offers only palliative approaches. With such a prognosis, effective treatment of metastatic and metastatic castrate-resistant prostate cancer (mCRPC) is an important element of the management of these patients. The second article of this two-part series focuses on the main management approaches, emerging therapies and nursing roles.
Written by:
Drudge-Coates L, Turner B. Are you the author?
Reference: Br J Nurs. 2012 Oct 11-24;21(18):S23-8.
PubMed Abstract
PMID: 23123814
